SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative ...
CHI Memorial announces it is the first in the Chattanooga region to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), or ...
SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...
G_enlarged prostate_BPH Randomized trial reveals no significant difference between Aquablation and TURP in improvements in lower urinary tract symptoms, peak urinary flow, and post-void residual ...
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through ...
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment globally, ...
Aquablation therapy is associated with 3-year outcomes similar to those of transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic ...
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has ...
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback